Brad L. Tade - 26 Jun 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
CFO and Treasurer
Signature
/s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact
Issuer symbol
ADMA
Transactions as of
26 Jun 2025
Net transactions value
-$181,019
Form type
4
Filing time
30 Jun 2025, 21:02:09 UTC
Previous filing
27 Feb 2025
Next filing
28 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tade Brad L. CFO and Treasurer C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON /s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact 30 Jun 2025 0002030561

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Tax liability $181,019 -9,838 -3.8% $18.40 246,542 26 Jun 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
F2 Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 72,400 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F3 (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F4 (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 24,415 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.